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1. Abstract
Membrane chromatography is consistently used in the purification of viral  
particles like adenoviruses or influenza viruses. The lack of traditional  
diffusion-based limitations of porous particles and increased binding capacities  
in a disposable format make it a viable alternative to bead chromatography.  
This poster presents a novel cellulose based stationary membrane whose specific 
surface area is designed for maximum virus accessibility.  
The membrane also utilizes highly selective pseudo-affinity ligands for  
influenza viruses resulting in an overall increase in selectivity and product  
recovery. The unique capabilities of this media not only contribute to reduction  
of the costs associated with the bind & elute purification of viruses but may  
also constitute one step forward in the development of an optimized and  
efficacious purification platform process for the vaccine industry.
2. Mass transfer in membrane adsorbers
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3. Design of the membrane adsorber stationary phase
Rationale of optimization:
I.  remove the hydrogel present in membrane adsorbers for polishing applications
II.   reduce | optimize the distribution and size of the pores of the precursor membrane
III.  couple the ligand directly to the precursor membrane
Figure 2: Schematic representation of the stationary phase design.
Left: Conventional membrane adsorber with 3D-hydrogel (e.g. Sartobind® S)
Right: Membrane adsorber specifically designed for virus capture
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Figure 3: Tailoring the permeability and the specific surface area by pore size optimization.
Optimization of cellulose precursor membranes for virus purification.
4. Adding affinity ligands
Sulfation of the cellulose based stationary phases generated sulfated cellulose
membrane adsorbers (SCMA) which exhibit pseudo-affinity interactions with
Influenza viruses.
During development the prototype testing was performed with model systems:
l  Ammonium-functionalized latex beads (100 nm) were used as virus mimics
l  Lysozyme was used as model contaminant
Figure 4: Prototype testing using model systems.
Left: SEM image of ammonium-functionalized latex beads bound to the surface of a SCMA prototype.
Right: Selectivity plot of SCMA prototypes in comparison to Sartobind® S. The gain in selectivity is clearly demonstrated by  
the increase in binding capacity for large particles and the reduced binding capacity for small model contaminants.
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5. Binding capacity and recovery of Influenza virus
Evaluation of the newly developed SCMA was performed in comparison to
commercially available sulfated cellulose resins.
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HA-activity HAU/mlmemb SCMA  
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SCMA 4,95E+06
Resin C 1,02E+06 486%
Resin D 7,34E+05 673%
  
Virus  
particles
particles/mlmemb SCMA  
vs resin
SCMA 9,94E+12
Resin C 2,08E+12 486%
Resin D 1,50E+12 673%
Figure 5: Binding capacity study with Influenza A/ 
Puerto Rico/8/1934 (H1N1).
SCMA —  Resin C —  Resin D —
Column volume: 0.08 mL (SCMA), 0.18 mL (Resin C, Resin D)
Flow rate: 3.75 CV/min (SCMA), 0.67 CV/min (Resin C),  
1 CV/min (Resin D)
Feed: 30 kHAU/mL in 10mM TRIS, pH7.4
Table 1: Results of DBC study
3,6 0,8
88,5 92,9
1,8 0,6
100,3
102,7
1,1 0,1
91,2 92,4
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1,8 4,6
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1,6 3,7
101,0100,3
2,2 5,8
108,3
Flow through Wash Elution TOTAL
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Figure 6: Recovery study with Influenza A/Puerto Rico/8/1934 (H1N1).
Legend and experimental conditions: see figure 5
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6. Summary
The newly developed sulfated cellulose membrane adsorber exhibits 5 times  
higher binding capacity for Influenza A virus than commercially available resins 
while offering comparable recovery and purity.
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Figure 1: Schematic illustration highlighting the dependence of dynamic  
binding capacity on the size of the molecule and the flow rate for gel  
and membrane chromatography. In membrane adsorbers mass transfer is  
dominated by convective flow. 
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Why virus capture on membrane adsorber?
Resin Bead Membrane Adsorber
21 July 2015 Page   14
Membrane development - stationary phase design – higher capacity 
for large molecules – less capacity for small molecules
Model system for development:
 Ammonium-functionalized latex beads (100 nm) used as virus mimics
 Lysozyme used as model contaminant
Sulfated cellulose membrane adsorber prototypes (SCMA) compared to Sartobind S
OSO3-Pseudo affinity SC ligand:
Sartobind Sulfated Cellulose  - 8 to 9-fold higher dynamic binding
capacity for Influenza A at ~20 times higher flow rate
 Sartobind Sulfated Cellulose (SC)
 Resin C
 Resin D
HAU/mlmemb SC vs resin
 Sartobind SC 2,47E+06
 Resin C 3,31E+05 7.5x
 Resin D 2,88E+05 8.6x
Chromatography conditions
Feed: 9-14kHAU/mL, adjusted to 4mS/cm
Flow rate: Resin C: 0.17 CV/min
Resin D: 0.25 CV/min
Sartobind SC: 3.75 MV/min
Equilibration: 10mM TRIS, 50mM NaCl (pH7.4, 4mS/cm)
Load: Feed
Wash: 10mM TRIS, 50mM NaCl (pH7.4, 4mS/cm)
Elution: 10mM TRIS, 2M NaCl (pH7.4, 148mS/cm)
Regeneration: Resin C: 0.15M NaOH, 2M NaCl
Resin D: 1M NaOH, 2M NaCl
Sartobind SC: 1M NaOH, 2M NaCl
Dynamic binding capacity at 10% breakthrough, Influenza A/Puerto 
Rico/8/1934 (H1N1) HA-activity
::
Sartobind Sulfated Cellulose – Recovery for Influenza – 7 to 8% higher
recovery than resins – purity on same level
 Sartobind Sulfated Cellulose (SC)
 Resin C
 Resin D
Influenza A/Puerto Rico/8/1934 (H1N1) recovery / removal in %:
Chromatography conditions
Feed: 12-14kHAU/mL, adjusted to 4mS/cm
Flow rate: Resin C:   0.17 CV/min
Resin D:   0.25 CV/min
Sartobind SC: 3.75 MV/min
Equilibration: 10mM TRIS, 50mM NaCl (pH7.4, 4mS/cm)
Load: Feed until 70% of DBC
Wash: 10mM TRIS, 50mM NaCl (pH7.4, 4mS/cm)
Elution: 10mM TRIS, 650-850mM NaCl (pH7.4)
Regeneration: Resin C: 0.15M NaOH, 2M NaCl
Resin D: 1M NaOH, 2M NaCl
Sartobind SC: 1M NaOH, 2M NaCl
Recovery % SC vs resin
 Sartobind SC 81.2
 Resin C 73.1 - 8.1%
 Resin D 74.1 - 7.1%
Latest data show up to 23-fold binding capacity compared to resins.
Influenza A/Puerto Rico/8/
1934 (H1N1)
HAU/mlmemb SC vs resin
 Sartobind SC 2,47E+06
 Resin C 3,31E+05 7.5x
 Resin D 2,88E+05 8.6x
Influenza A/Switzerland/
9715293/2013 (H3N2)
HAU/mlmemb SC vs resin
 Sartobind SC 1.64E+06
 Resin C No binding 1.64E+06
 Resin D No binding 1.64E+06
Influenza B /Phuket/
3073/2013
HAU/mlmemb SC vs resin
 Sartobind SC 1.11E+06
 Resin C 5.26E+04 21.1x
 Resin D 4.79E+04 23.2x
DBC10% [HAU mL matrix-1]  Seasonal vaccines bind
 DBC 10% : min.1.0 E+6 HAU/mlmemb
Based on Sartobind SC pico 0.08 mL
 Can be integrated in 96well plates, 
capsules and cassettes (up 100 L)
 Stable to 1 N NaOH cleaning
Fortuna AR, et al., Sulfated cellulose
membrane adsorbers as a platform
technology for purification of cell-culture
derived influenza vaccines, 11th Int
Congress on Membranes and Membrane 
Processes, 2017 July 29 – August 4, San 
Francisco, USA, 
Calculated productivity with continuous upstream (~4000 L per hour): 
40 million doses with 54 liter Sartobind Sulfated Cellulose within 1 day
up to 100 L From 0.08 mL...
34 x cassettes x 1.6 L = 54 L
Min. Dynamic binding capacity 10% HAU/ml memb 1.0E+06 
Antigen binding capacity membrane 10% μg/L
311.000 
Percentage loaded to avoid breakthrough % 80%
Antigen concentration bioteactor μg/L 6730
Regeneration 1 N NaOH MV 1,5
Membrane volume all cassettes L 54,4
Flow rate L/min 180
Yield % 80%
Number of cycles per hour n 2
Working hours in case of pandemics: hours 24
Number of influenza doses per day n 40.341.799 
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